Drug intelligence / Profile preview

budesonide + prednisone

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Inhalation

Overview

Budesonide + prednisone is a combination of two corticosteroid medications used to treat inflammatory conditions. Budesonide is a locally-acting glucocorticoid that primarily works in the gut, liver, or respiratory tract with minimal systemic absorption. Prednisone is a systemic corticosteroid that affects the entire body and requires conversion to prednisolone in the liver to become active. This combination may be prescribed during severe flare-ups of conditions like asthma, COPD, or inflammatory bowel diseases when more potent anti-inflammatory effects are needed.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on budesonide + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on budesonide + prednisone.

Explore the full profile